Jobs
View more job listings or post a job
MilliporeSigma Emerging Biotech Market Development Manager - San Fransisco
How Cancer LLC Social Media Digital Marketing Specialist  
How Cancer LLC Syndicated National Writer - Cancer 
University of California, Davis SCREENING SUPERVISOR
InnoAlliance Scientist/Sr Scientist of Bioanalysis & Biomarkers
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Post a job

Symposium

PBSS-SOT Joint Symposium: Combination Therapy Drug Development: Fundamentals, Advances, and Case Studies


Speakers: Joseph Francisco (CRL), Philip Gatti (FDA), Paul Feldman (Intarcia), Jonathan Wang (Genentech), Lynn Genarro (Genentech), Rosa Chan (UCSF), Anne Chester (Gilead), Rebecca Begley (Gilead), Jessica Hawes (FDA)
Organizers:
Date: 2017-05-16
Time: 7:30-17:30 Pacific Time
Registration fee: (USD): Regular: $50; Academic: $50; Students or Unemployed: $50
Location: South San Francisco Conference Center (255 South Airport Boulevard, South San Francisco, CA 94080)
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2017-05-15  (it will close sooner if the seating cap is reached)

About the Topic

Morning Session

7:30 am – 8:30 am       Registration & Breakfast

8:30 am – 8:45 am       Opening message from The NorCal & PBSS Presidents (Toufan Parman, PhD, DABT, Director, General Toxicology, SRI; Shichang Miao, PhD, VP, Preclinical Development & Clinical DMPK, ChemoCentryx)

8:45 am – 9:20 am       Introduction to the Preclinical Development of Combination Therapies (Joseph Francisco, CRL)

9:20 am – 9:55 am       Safety Assessment of Combination Therapeutic Agents: Regulatory Guidance and Expectations (Philip Gatti, FDA)

9:55 am – 10:30 am     Addressing The Challenges With The Discovery of Combination Peptide (Paul Feldman, Intarcia)

10:30 am – 10:45 am   Coffee Break

10:45 am – 10:55 am   Sponsor Platform AM: TBD

10:55 am – 11:30 am   Challenges and solutions in the development of multi-analyte bioanalytical methods (Jonathan Wang, Genentech)

11:30 am – 12:05 am   Presentation 4: TBD (Lynn Genarro, Genentech)

12:05 pm – 1:30 pm    Lunch Break: Lunch with Experts, Posters

Afternoon Session

1:30 pm – 1:45 pm      Chapter announcements and acknowledgements

1:45 am – 2:05 am       NorCal Student Award presentation: Evaluation of DILI Predictive Hypotheses in Early Drug Development (Rosa Chan, UCSF)

2:05 pm – 2:40 pm      Combination Toxicity Study of 2 Approved Cardiovascular Drugs (Anne Chester, Gilead)

2:40 pm – 3:00 pm      Coffee Break

3:00 pm – 3:10 pm      Sponsor Platform PM: TBD

3:10 pm – 3:45 pm      Clinical Pharmacology considerations for development of combination products (Rebecca Begley, Gilead)

3:45 pm – 4:20 pm      Combination Drug Applications: Nonclinical Reviewer Perspectives (Jessica Hawes, FDA)

4:20 pm – 4:35 pm      Closing Remarks

4:35 pm – 5:50 pm      Reception & Networking


2025-01-22, [In-Person] Small-Molecule Formulation for Discovery & Early Development (jointly by PBSS / AAPS-BADG / Syner-G)
2025-02-06, [In-Person] Intellectual Property (IP) Strategies and Best Practices
2025-02-13, [Free Online] The Science and Stories of Promising Biotech Startups
2025-02-26, [In-Person] Demystifying Biopharma Business Development: Understanding the Process and Thriving as a BD Professional
2025-03-07, [In-Person] Clinical Trial Planning and Conduct: Fundamentals, Strategies and Best Practices
2025-03-27, [Free Online Workshop] Biotech Financing 101: from Angels, Government Agencies, Foundations and VCs
2025-04-09, [In-Person] Cell Therapy Discovery and Development: Fundamentals, Strategies and Best Practices (jointly by PBSS and RAPS-SF)
2025-04-22, [Free Online Workshop] Career Transitions for Research Scientists: BD/Sales in CROs, CDMOs, and Lab Products & Instruments
2025-04-25, [In-Person] Drug Metabolism Fundamentals and Metabolite Identification
©Pharmaceutical & BioScience Society, International; Last Modified: 1/15/2025; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Aliri Bioanalysis to the rescue! Pioneers in LCMS & Oligo bioanalysis w/ 30+ years of experience putting dev. programs back on track with quality data & fast timelines.
Hypha Discovery Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
Allucent Experts bringing development innovation w/ClinPharm Modeling & Simulation deliverables to inform dose, study design, modeling+development strategies.
Submit a Text Ad